伊立替康联合5-氟尿嘧啶/亚叶酸钙治疗晚期大肠癌的临床观察

Irinotecan combined with 5-Fu/CF in the treatment of advanced colorectal cancer

目的:观察伊立替康(CPT-11)联合5-氟尿嘧啶(5-FU)与亚叶酸钙(CF)治疗晚期大肠癌的临床疗效和不良反应。方法:24例晚期大肠癌患者采用CPT-11 180 mg/m2,化疗第一天ivgtt 90 min;CF 100 mg/d,ivgtt,d1～5;5-FU 500 mg/m2,ivgtt,d1～5,21 d为1周期,治疗2个周期以上评价疗效。结果:24例均可评价疗效,CR 0例,PR 9例,NC 7例,PD 8例,有效率(CR+PR)37.5%。中位疾病进展时间(TTP)6.7个月。不良反应主要为迟发性腹泻、中性粒细胞减少及乙酰胆碱综合征。结论:CPT-11联合5-Fu/CF治疗晚期大肠癌疗效肯定,安全性好,不良反应可耐受,可使大部分患者临床获益。

Objective：To evaluate the efficacy and toxicity of irinotecan （CPT-11） combined with 5-Fu/CF in the treatment of ad- zanced colorectal cancer. Methods：24 patients with advanced colorectal cancer were treated with irinotecan 180 mg/m^2,ivgtt,the first tay;CF 100 mg/d,ivgtt,for 1-5 days;5-Fu 500 mg/m^2,ivgtt,for 1-5 days,and repeated every 3 weeks. The efficacy was evaluated after two cycles. Results：In 24 evaluable patients,The total effective rate was 37.5% in the 24 patients with advanced colorectal cancer,CR was 0：PR was 9;NC was 7;PD was 8. TIP was 6.7 months. The common treatment related adverse events were delayed diarrhea and aeutrepenia and cholinergic syndrome.Conclusion ：CPT-11 combined with 5-Fu/CF for treating patients with advanced colorectal cancer is an active regimen：Its side effects are tolerable and it makes most patients benefit clinically.